Aclaris Therapeutics, Inc.ACRSEarnings & Financial Report
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for immunological, inflammatory, and dermatological diseases. Its pipeline includes candidates for unmet needs like alopecia areata and vitiligo, serving global patient groups.
Revenue
$2.8M
Gross Profit
$2.1M
Operating Profit
$-12.9M
Net Profit
$-11.0M
Gross Margin
77.4%
Operating Margin
-464.7%
Net Margin
-397.2%
YoY Growth
48.0%
EPS
$-0.15
Aclaris Therapeutics, Inc. Q2 FY2024 Financial Summary
Aclaris Therapeutics, Inc. reported revenue of $2.8M (up 48.0% YoY) for Q2 FY2024, with a net profit of $-11.0M (up 62.8% YoY) (-397.2% margin). Cost of goods sold was $624.0K, operating expenses totaled $15.0M.
Key Financial Metrics
| Total Revenue | $2.8M |
|---|---|
| Net Profit | $-11.0M |
| Gross Margin | 77.4% |
| Operating Margin | -464.7% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
Aclaris Therapeutics, Inc. Q2 FY2024 revenue of $2.8M breaks down across 2 segments, led by Dermatology Therapeutics Segment at $2.1M (77.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Dermatology Therapeutics Segment | $2.1M | 77.4% |
| Other | $625.0K | 22.6% |
Aclaris Therapeutics, Inc. Annual Revenue by Year
Aclaris Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $7.8M |
| 2024 | $18.7M |
| 2023 | $31.2M |
| 2022 | $29.8M |
Aclaris Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aclaris Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.3M | -85.9% | N/A | N/A |
| Q3 FY2025 | $3.3M | -24.1% | $-14.6M | -443.0% |
| Q2 FY2025 | $1.8M | -35.8% | $-15.4M | -868.3% |
| Q1 FY2025 | $1.5M | -39.3% | $-15.1M | -1036.8% |
| Q4 FY2024 | $9.2M | -47.6% | $-96.6M | -1048.3% |
| Q3 FY2024 | $4.3M | -53.2% | $-7.6M | -174.6% |
| Q2 FY2024 | $2.8M | +48.0% | $-11.0M | -397.2% |
| Q1 FY2024 | $2.4M | -5.1% | $-16.9M | -706.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.8M | $4.3M | $9.2M | $1.5M | $1.8M | $3.3M | $1.3M |
| YoY Growth | -5.1% | 48.0% | -53.2% | -47.6% | -39.3% | -35.8% | -24.1% | -85.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $174.1M | $161.1M | $182.4M | $220.3M | $198.1M | $189.1M | $175.5M | $160.5M |
| Liabilities | $32.1M | $27.2M | $52.2M | $64.8M | $54.0M | $57.4M | $55.4M | $57.4M |
| Equity | $142.0M | $133.8M | $130.2M | $155.6M | $144.1M | $131.7M | $120.1M | $103.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.8M | $-12.3M | $22.0M | $-8.9M | $-13.1M | $-10.0M | $-10.9M | $-47.1M |